As of November 10, 2026, ArriVent Biopharma, Inc. is a publicly traded company (Nasdaq: AVBP). The largest holder reporting an active stake on Schedule 13D is OrbiMed, at 5.8%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Infinitum Asset Management, LLC (9.9%), Hillhouse Investment Management, Ltd. (9.5%), BlackRock (6.8%) (Schedule 13D/A, October 8, 2026).
Is this your company?
About to sign with, pay or invest in ArriVent Biopharma, Inc.? See the free Snapshot first.
Free to see. No signup.
Is ArriVent Biopharma, Inc. a real, registered company?
- ArriVent BioPharma, Inc. files with the SEC under CIK 1868279 (its SEC filings).
- Its shares are listed under the ticker AVBP on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Newtown Square, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ArriVent Biopharma, Inc. in our court records and SEC 8-K records (as of 2026-11-10).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are ArriVent Biopharma, Inc.'s owners and officers?
ArriVent Biopharma, Inc.: incorporated in Delaware; business address in Newtown Square, Pennsylvania; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-05).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2022-12-29)
- : Director (Form D, 2022-12-29)
- : Director (Form D, 2022-12-29)
- : Director (Form D, 2022-12-29)
- : Director (Form D, 2022-12-29)
- : Director (Form D, 2022-12-29)
- : Director (Form D, 2022-12-29)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 5.8% |
| Schedule 13G, 2026-10-13 | Vivo Opportunity, LLC | 5% |
| Schedule 13D/A, 2026-10-08 | Orbimed Advisors LLC | 5.8% |
| Schedule 13G/A, 2026-07-27 | Blackrock, Inc. | 6.8% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 6.8% |
| Schedule 13G/A, 2026-03-05 | Sofinnova Venture Partners Xi, L.P. ("Svp Xi") | 4.1% |
| Schedule 13G/A, 2026-02-17 | Hillhouse Investment Management, LTD. | 9.5% |
| Schedule 13G/A, 2026-02-17 | Infinitum Asset Management, LLC | 9.9% |
| Schedule 13G/A, 2026-01-30 | The Vanguard Group | 4.52% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 5.6% |
| Schedule 13G/A, 2025-11-14 | Octagon Capital Advisors LP | 4.9% |
| Schedule 13G/A, 2025-11-05 | Fmr LLC | 8.4% |
Questions about who owns ArriVent Biopharma, Inc.
Who owns ArriVent Biopharma, Inc.?
On this page, 6 holders' latest ownership filings report 5% or more of ArriVent Biopharma, Inc.: Infinitum Asset Management, LLC (9.9%, Schedule 13G/A, filed 2026-02-17), Hillhouse Investment Management, LTD. (9.5%, Schedule 13G/A, filed 2026-02-17), Blackrock, Inc. (6.8%, Schedule 13G/A, filed 2026-07-27), Fmr LLC (5.8%, Schedule 13G/A, filed 2026-11-05) and Orbimed Advisors LLC (5.8%, Schedule 13D/A, filed 2026-10-08); 1 more is listed above.
Who are the largest shareholders of ArriVent Biopharma, Inc.?
By the share each holder's latest filing reports, the largest holders of ArriVent Biopharma, Inc. on this page are Infinitum Asset Management, LLC (9.9%), Hillhouse Investment Management, LTD. (9.5%) and Blackrock, Inc. (6.8%).
When did Infinitum Asset Management, LLC buy into ArriVent Biopharma, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Infinitum Asset Management, LLC on this page is the Schedule 13G/A, filed 2026-02-17, reporting 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on ArriVent Biopharma, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on ArriVent Biopharma, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ArriVent Biopharma, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own ArriVent Biopharma, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- HHLR Advisors, Ltd., a 10% owner: 3,929,117 shares (7.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-02-03).
- Hillhouse Investment Management, Ltd., a 10% owner: 3,929,117 shares (7.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-02-03).
- , the chief operating officer: 570,906 shares (1.1% of shares outstanding), 176,429 held directly and 394,477 indirectly (Form 4, 2026-11-02).
Shares outstanding: 51,723,074 as of 2026-11-05, from the company's latest SEC cover page.
How much has ArriVent Biopharma, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2022-12-29 | $110M | $145M |
Keep reading
More on ArriVent Biopharma, Inc. and the records around it.
ArriVent Biopharma, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- Sofinnova Venture Partners XI, L.P. ("SVP XI") also filed stake reports on 1 other company: NextCure, Inc. (Mar 2026)
- Hillhouse Investment Management, Ltd. also filed stake reports on 2 other companies: Smart Share Global Limited (May 2026), Webull Corp (Feb 2026)
- HBM Healthcare Investments (Cayman) Ltd. also filed stake reports on 7 other companies: Chemomab Therapeutics Ltd. (Sep 2026), ALX ONCOLOGY HOLDINGS INC (May 2026), IO Biotech, Inc. (Apr 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/arrivent-biopharma